Last reviewed · How we verify
NCT05868928
Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
trial testing Magnetic resonance imaging (MRI) in Brain Metastases in 132 participants. Currently enrolling.
30 July 2026
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 132 |
| Start date | 7 December 2023 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 July 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Magnetic resonance imaging (MRI)
- Diffusion-weighted MRI
- Arterial spin labeling (ASL)
- Dynamic susceptibility contrast-MRI (DSC-MRI)
Conditions studied
- Brain Metastases — all drugs for Brain Metastases →
- Radiosurgery — all drugs for Radiosurgery →
Sponsor
Asan Medical Center
Who can join
18 and older, any sex, with Brain Metastases or Radiosurgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
MRI-based habitat imaging in cancer treatment: current technology, applications, and challenges.
Li S, Dai Y, Chen J, Yan F, et al · · 2024 · cited 43× · PMID 39148139 · DOI 10.1186/s40644-024-00758-9 -
Assessment of imaging risks for recurrence after stereotactic radiosurgery for brain metastases (IRRaS-BM).
Roh YH, Park JE, Park SY, Cho YH, et al · · 2024 · cited 1× · PMID 39026289 · DOI 10.1186/s12885-024-12636-5
Verify or expand the search:
- PubMed search for NCT05868928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnetic resonance imaging (MRI)
Trials testing the same drug.
- NCT07447076 — Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) · Phase 2 · not yet recruiting
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07121972 — Mirai-MRI: Validation of AI Models for Breast Cancer Risk · NA · recruiting
- NCT06246942 — Physiology of Human Brain Connectivity · NA · recruiting
- NCT06377332 — Biomarkers of Dementia in Chronic Sleep and Breathing Disorders · unknown
Other recruiting trials for Brain Metastases
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
- NCT07227610 — Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · Phase 2 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05868928 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05868928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing